46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02264301 (ClinicalTrials.gov) | August 2014 | 3/10/2014 | Qingkailing Injection Versus Puerarin Injection on Withdrawal Rate of Corticosteroids in Patients With Active Rheumatoid Arthritis | The Effect of Qingkailing Injection on Corticosteroids Withdrawal Rate in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Puerarin injection 400 mg;Drug: Qingkailing injection 40 ml | Chengdu PLA General Hospital | NULL | Enrolling by invitation | 18 Years | 75 Years | All | 150 | N/A | China |
| 2 | NCT02254655 (ClinicalTrials.gov) | November 2013 | 18/11/2013 | The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis | The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis, a Controlled and Randomized Trial | Rheumatoid Arthritis | Drug: Puerarin injection 400 mg;Drug: Control | Chengdu PLA General Hospital | NULL | Completed | 18 Years | 75 Years | All | 119 | Phase 2 | China |